-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is from the NEJM Journal Watch
Does Methotrexate Use Confer Risk for Developing Melanoma? Comments on whether methotrexate poses a risk
for melanoma by Thomas L.
Schwenk, MD
It takes one case of melanoma to cause one melanoma
in tens of thousands to hundreds of thousands of patients treated with low-dose methotrexate.
.
Articles that are commented on
.
NEJM Medical Frontiers is translated several times a week, published on the app and official website, and selected 2-3 articles are published
on WeChat.
Copyright Information This article is translated, written or commissioned
by Jiahui Medical Research and Education Group (J-Med) and the New England Journal of Medicine (NEJM).
The full Chinese translation and the figures contained therein are exclusively licensed
by NEJM Group.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement and the copyright owner reserves the right to
pursue legal responsibility.
Does Methotrexate Use Confer Risk for Developing Melanoma? Comments on whether methotrexate poses a risk
for melanoma by Thomas L.
Schwenk, MD
It takes one case of melanoma to cause one melanoma
in tens of thousands to hundreds of thousands of patients treated with low-dose methotrexate.
Some small or poorly controlled studies suggest that methotrexate use may be associated with
an excess risk of melanoma.
In this meta-analysis, investigators identified 6 randomized trials and 6 observational studies that included low-dose methotrexate exposure (5~30 mg per week) and melanoma outcome data; Almost all of the 17,000 melanoma cases came from large cohort and case-control studies
.
All 10 studies had a follow-up period of at least two years
.
The pooled data showed an excess risk of melanoma that had just reached significant levels (relative risk, 1.
15).
When a study of more than 3,000 melanoma cases was excluded, the relative risk was no longer significant (1.
11).
According to the incidence of melanoma in Australia (a high-risk country for melanoma) and North America, receiving low-dose methotrexate treatment for every 41,000~196,000 patients will lead to an increase in
melanoma cases.
.
Articles that are commented on
Yan MK et al.
Association between low-dose methotrexate exposure and melanoma: A systematic review and meta-analysis.
JAMA Dermatol 2022 Aug 31; [e-pub].
(https://doi.
org/10.
1001/jamadermatol.
2022.
3337)
NEJM Journal Collection
Published by NEJM Group, NEJM Journal Watch invites internationally renowned doctors to review important papers in the medical field to help doctors understand and apply the latest developments.
NEJM Medical Frontiers is translated several times a week, published on the app and official website, and selected 2-3 articles are published
on WeChat.
Copyright Information This article is translated, written or commissioned
by Jiahui Medical Research and Education Group (J-Med) and the New England Journal of Medicine (NEJM).
The full Chinese translation and the figures contained therein are exclusively licensed
by NEJM Group.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement and the copyright owner reserves the right to
pursue legal responsibility.
